Melguizo Alonso, Consolación Author
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
- Antonio Oliver, Jaime
- Ortiz, Raul
- Melguizo, Consolacion
- Juan Alvarez, Pablo
- Gomez-Millan, Jaime
- Prados, Jose
BMC CANCER - 11/07/2014
- SJR Quartile: Q1
- JCR Impact Factor: 3.362 (2014)
- CiteScore: 5.4 (2020)
- SJR: 1.719 (2014
- SNIP: 1.267 (2014
- JCR 5-year Impact Factor: 3.77
- JCR Categories: ONCOLOGY
- SJR Categories: Oncology (Q1); Cancer Research (Q2); Genetics (Q2)
- Scopus
- ORCID
- Web of Science
Inhibition of growth and induction of apoptosis in human breast cancer by transfection of gef gene
- Boulaiz, H
- Prados, J
- Melguizo, C
- Garcia, AM
- Marchal, JA
- Ramos, JL
- Carrillo, E
- Velez, C
- Aranega, A
British Journal of Cancer - 7/07/2003
- JCR Quartile: Q1 (2003)
- SJR Quartile: Q1
- JCR Impact Factor: 3.894 (2022)
- Category normalized Impact: 0.49 (2003)
- CiteScore: 10.7 (2020)
- SJR: 1.662 (2003
- SNIP: 1.37 (2003
- SJR Categories: Cancer Research (Q1); Oncology (Q1)
- Scopus
- ORCID
- Web of Science
GR-891: A novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells
- Marchal, JA
- Prados, J
- Melguizo, C
- Gomez, JA
- Campos, J
- Gallo, MA
- Espinosa, A
- Arena, N
- Aranega, A
British Journal of Cancer - 23/02/1999
- JCR Quartile: Q1 (1999)
- SJR Quartile: Q1
- JCR Impact Factor: 3.282 (2022)
- Category normalized Impact: 0.309 (1999)
- CiteScore: 10.7 (2020)
- SJR: 1.242 (1999
- SNIP: 1.269 (1999
- SJR Categories: Cancer Research (Q1); Oncology (Q1)
- Scopus
- ORCID
- Web of Science
Tumour malignancy loss and cell differentiation are associated with induction of gef gene in human melanoma cells
- Boulaiz, H.
- Prados, J.
- Melguizo, C.
- Marchal, J. A.
- Carrillo, E.
- Peran, M.
- Rodriguez-Serrano, F.
- Martinez-Amat, A.
- Caba, O.
- Hita, F.
- Concha, A.
- Aranega, A.
BRITISH JOURNAL OF DERMATOLOGY - 1/08/2008
10.1111/j.1365-2133.2008.08688.x
- JCR Quartile: Q1 (2008)
- SJR Quartile: Q1
- JCR Impact Factor: 3.489 (2022)
- Category normalized Impact: 0.393 (2008)
- CiteScore: 11.6 (2020)
- SJR: 1.588 (2008
- SNIP: 1.707 (2008
- SJR Categories: Dermatology (Q1); Medicine (miscellaneous) (Q1)
- Scopus
- ORCID
- Web of Science
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
- Quiñonero F.
- Mesas C.
- Doello K.
- Cabeza L.
- Perazzoli G.
- Jimenez-Luna C.
- Rama A.
- Melguizo C.
- Prados J.
Cancer Biology and Medicine - 1/11/2019
10.20892/j.issn.2095-3941.2019.0252
- SJR Quartile: Q1
- JCR Impact Factor: 5.432 (2019)
- CiteScore: 6.8 (2020)
- SJR: 1.927 (2019
- SNIP: 1.657 (2019
- JCR Categories: MEDICINE, RESEARCH & EXPERIMENTAL
- SJR Categories: Cancer Research (Q1); Oncology (Q1)
- Scopus
- ORCID
- Web of Science
Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells
- Prados J.
- Melguizo C.
- Rama A.R.
- Ortiz R.
- Segura A.
- Boulaiz H.
- Vélez C.
- Caba O.
- Ramos J.L.
- Aránega A.
Cancer Chemotherapy and Pharmacology - 1/5/2010
- JCR Quartile: Q4 (2010)
- SJR Quartile: Q1
- JCR Impact Factor: 2.759 (2010)
- Category normalized Impact: 0.631 (2010)
- CiteScore: 5.5 (2020)
- SJR: 1.219 (2010
- SNIP: 0.96 (2010
- JCR 5-year Impact Factor: 2.627
- JCR Categories: ONCOLOGY
- SJR Categories: Oncology (Q1); Pharmacology (Q1); Pharmacology (medical) (Q1); Toxicology (Q1); Cancer Research (Q2)
- Scopus
- ORCID
- Web of Science
Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance
- Melguizo C.
- Prados J.
- Luque R.
- Ortiz R.
- Rama A.R.
- Caba O.
- Rodríguez-Serrano F.
- Álvarez P.J.
- Aránega A.
Cancer Chemotherapy and Pharmacology - 1/2/2013
- SJR Quartile: Q1
- JCR Impact Factor: 2.571 (2013)
- CiteScore: 5.5 (2020)
- SJR: 1.122 (2013
- SNIP: 0.974 (2013
- JCR 5-year Impact Factor: 2.56
- JCR Categories: PHARMACOLOGY & PHARMACY
- SJR Categories: Pharmacology (Q1); Pharmacology (medical) (Q1); Toxicology (Q1); Cancer Research (Q2); Oncology (Q2)
- Scopus
- ORCID
- Web of Science
Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer
- Rosa Rama A.
- Hernández R.
- Perazzoli G.
- Cabeza L.
- Melguizo C.
- Vélez C.
- Prados J.
CANCER GENE THERAPY - 1/1/2019
- SJR Quartile: Q2
- JCR Impact Factor: 4.534 (2019)
- CiteScore: 8.1 (2020)
- SJR: 1.535 (2020
- SNIP: 1.113 (2020
- JCR 5-year Impact Factor: 3.997
- JCR Categories: BIOTECHNOLOGY & APPLIED MICROBIOLOGY
- SJR Categories: Molecular Medicine (Q2); Cancer Research (Q3); Molecular Biology (Q3)
- Scopus
- ORCID
- Web of Science
The antitumor activity of sodium selenite alone and in combination with gemcitabine in pancreatic cancer: An in vitro and in vivo study
- Doello K.
- Mesas C.
- Quiñonero F.
- Perazzoli G.
- Cabeza L.
- Prados J.
- Melguizo C.
- Ortiz R.
Cancers - 1/7/2021
- JCR Quartile: Q1 (2021)
- JCR Impact Factor: 6.575 (2022)
- Category normalized Impact: 0.828 (2021)
- JCR 5-year Impact Factor: 6.886
- JCR Categories: ONCOLOGY
- Scopus
- ORCID
- Web of Science
Cancer Stem Cells in Sarcomas: In Vitro Isolation and Role as Prognostic Markers: A Systematic Review
- Maria Angeles Chico
- Cristina Mesas
- Kevin Doello
- Francisco Quiñonero
- Gloria Perazzoli
- Raul Ortiz
- Jose Prados
- Consolacion Melguizo
Cancers - 25/04/2023
- Scopus
- ORCID
- Web of Science
The story of a doctoral thesis: GEF, a new gene with applications in anti-tumor gene therapy
- Boulaiz, H
- Prados, J
- Melguizo, C
- Marchal, JA
- Carrillo, E
- Velez, C
- Fernandez, JE
- Alvarez, L
- Caba, O
- Aranega, A
CELLULAR AND MOLECULAR BIOLOGY - 06/2003
- JCR Quartile: Q4 (2003)
- SJR Quartile: Q1
- JCR Impact Factor: 1.153 (2022)
- SJR Categories: Medicine (miscellaneous) (Q1)
Role of cancer stem cells of breast, colon, and melanoma tumors in the response to antitumor therapy
- Marchal J.
- García M.
- Boulaiz H.
- Perán M.
- Álvarez P.
- Prados J.
- Melguizo C.
- Aránega A.
Stem Cells and Cancer Stem Cells, Volume 3: Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury: Volume 3 - 1/1/2012
- Scopus
- ORCID
This author has no conferences.
This author has no patents.
Downregulated microRNAs in the colorectal cancer: Diagnostic and therapeutic perspectives
- Hernández R.
- Sánchez-Jiménez E.
- Melguizo C.
- Prados J.
- Rama A.R.
BMB Reports - 1/1/2018
- SJR Quartile: Q1
- JCR Impact Factor: 2.966 (2018)
- CiteScore: 6 (2020)
- SJR: 1.082 (2018
- SNIP: 0.952 (2018
- JCR 5-year Impact Factor: 2.838
- JCR Categories: BIOCHEMISTRY & MOLECULAR BIOLOGY
- SJR Categories: Medicine (miscellaneous) (Q1); Biochemistry (Q2); Molecular Biology (Q2)
- Scopus
- ORCID
- Web of Science
Correction: Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer (Cancer Gene Therapy, (2019), 10.1038/s41417-019-0137-3)
- Ballesteros A.
- Hernández R.
- Perazzoli G.
- Cabeza L.
- Melguizo C.
- Vélez C.
- Prados J.
CANCER GENE THERAPY - 1/1/2020
- JCR Impact Factor: 5.987 (2020)
- CiteScore: 8.1 (2020)
- SJR: 1.535 (2020
- SNIP: 1.113 (2020
- JCR 5-year Impact Factor: 5.358
- JCR Categories: MEDICINE, RESEARCH & EXPERIMENTAL
Synthesis, solubility and antitumor activity of maslinic acid derivatives
- Fuentes-Rios, D.
- Cepero, A.
- Garcia-Castro, M.
- Contreras-Caceres, R.
- Lopez-Romero, J. M.
- Luque, C.
- Cabeza, L.
- Melguizo, C.
- Prados, J.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS - 4/2022
Nanomedicine and Hyperthermia for the Treatment of Gastrointestinal Cancer: A Systematic Review
- Lidia Gago
- Francisco Quiñonero
- Gloria Perazzoli
- Consolacion Melguizo
- Jose Prados
- Raul Ortiz
- Laura Cabeza
Pharmaceutics - 13/06/2023
- Scopus
- ORCID
- Web of Science
Contact info
Email: melguizo@ual.es
h index
Scopus: 27
Web of Science: 30
i10 index
Scopus: 78
Web of Science: 90
Author profiles
-
ORCID
-
Web of Science ResearcherID
-
Scopus Author ID
-
Dialnet id
Research projects at UAL
-
Acronym CV20-78799Since: September 8, 2020Until: September 7, 2021Funded by: JUNTAFunding / grant amount: 60,000.00 EURRole: Investigador